NFKB1 and Hepatic steatosis: Conversely, inhibition of NF-κB in obese animals by a selective NF-κB inhibitor, celastrol, ameliorates pathophysiological processes such as obesity-induced kidney injury, insulin resistance, and hepatic steatosis [113,114,115].